



Faut-il faire plus que les veines pulmonaires en cas d'ablation de FA?

Dr Franck Halimi
Cabinet Médical de la Néva Paris

Liens d'intérêt

Consultant:


- Johnson & Johnson, Medtronic, Abbott, Boston Scientific, MicroPort

Recommendations for rhythm control/catheter ablation of AF (5)




Recommendations	Class	Level
<i>Techniques and technologies</i>		
Complete electrical isolation of the pulmonary veins is recommended during all AF catheter-ablation procedures.	I	A
If patient has history of CTI-dependent AFL or if typical AFL is induced at the time of AF ablation, delivery of a CTI lesion may be considered.	IIb	B
Use of additional ablation lesions beyond PVI (low voltage areas, lines, fragmented activity, ectopic foci, rotors, and others) may be considered but is not well established.	IIb	B


L'ablation par radiofréquence / 3D



La cryoablation




L'électroporation





2023 © 29ème Congrès du CNCH. Tous droits réservés - Toute reproduction même partielle est interdite.

Création de lignes d'ablation additionnelles




Ligne du toit et du SC




Haïssaguerre M. et al. JCE 2005; 16: 1125-37

Recherche de potentiels fragmentés




- arrêt de la FA 95%
- 91% RS à 1 an



STAR AF II



The phase map shows a focal source that emanates an impulse from the RIPV and initiates a couple (figure of 8) of reentrant drivers.



Alcoolisation de la veine de Marshall




Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation The VENUS Randomized Clinical Trial

Miguel Valderrábanos, MD; Leif E. Peterson, PhD; Vijay Swarup, MD; Paul A. Schurmann, MD; Akash Makkar, MD; Rahul N. Doshi, MD; David DeLurgio, MD; Charles A. Athill, MD; Kenneth A. Ellenbogen, MD; Andrea Natale, MD; Jayanthi Konermann, MD; Amish S. Dave, MD, PhD; Irakli Giorgberidze, MD; Hamid Afshar, MD; Michelle L. Southrie, RN; Raquel Bunge, RN; Carlos A. Morillo, MD; Neal S. Kleiman, MD

Figure 2. Time to Recurrence of Atrial Fibrillation or Tachycardia and Atrial Fibrillation Burden


A Atrial fibrillation or tachycardia occurrence after single procedure in as-randomized analysis



No. at risk

Vein of Marshall ethanol plus catheter ablation	185	180	174	153	129	116	108	89	68
Catheter ablation	158	157	148	132	110	95	86	69	54

B Atrial fibrillation or tachycardia occurrence after single procedure in as-treated analysis



No. at risk

Vein of Marshall ethanol plus catheter ablation	155	151	145	129	111	100	95	77	58
Catheter ablation	158	157	148	132	110	95	86	69	54


Attention aux flutter Gauches !



AFIDE trial

L'ablation par cathéter maintient le RS


- Pts with PAF and not responding to >1 antiarrhythmic drug therapy
 - Pts were followed for a 9-month effectiveness evaluation period after a 3-month blanking period



1. Wilber DJ et al. *JAMA* 2010;303:333-40


... et améliore la qualité de vie !

- Following the 3-month effectiveness evaluation period, patients in the catheter ablation group experienced clinically meaningful improvement in symptoms and QoL compared with the ADT group



• 1. Wilber DJ et al. JAMA 2010;303:333-40

L'ablation est plus efficace si réalisée précocement




- Delays in treatment with catheter ablation negatively impact on success rates and pt outcomes^{1,2}

- 1. Bunch TJ et al. *Heart Rhythm* 2013;10:1257-62.
2. Winkle RA et al. *Europace* 2012;14:646-52


L'ablation est plus efficace chez les pts jeunes

2023 © 29^{ème} Congrès du CNCH, Tous droits réservés - Toute reproduction même partielle est interdite.



2023 © 29^{ème} Congrès du CNCH, Tous droits réservés - Toute reproduction même partielle est interdite.

Moins de complications de l'ablation chez les jeunes




Les études cliniques randomisées RF vs. antiarythmiques ou aucun traitement

Study	Reference	Patients (n)	Age, years	Type of AF	Previous use of AAD	Ablation technique	Repeat ablation in the ablation group	Crossed to ablation in the AAD group	AF free at 1 year	
									Ablation	AAD
Kittayaphong et al. 2003	Online	30	55 ± 10 (ablation) 47 ± 15 (AAD)	Paroxysmal, persistent	≥1 ^a	PVI + LA lines + CTI ablation + RA lines	Not stated	Not stated	79%	40%
Wazni et al. 2005 (RAAFT)	I34	70	53 ± 8 (ablation) 54 ± 8 (AAD)	Mainly paroxysmal	No	PVI	12% ^b	49% ^c	87%	37%
Stabile et al. 2005 (CACAF) ^d	Online	245	62 ± 9 (ablation) 62 ± 10 (AAD)	Paroxysmal, persistent	≥2	PVI + LA lines ± CTI ablation	No exact data	57%	56%	9%
Oral et al. 2006 ^e	Online	245	57 ± 9	Persistent	≥1 (mean 2.1 ± 1.2)	CPVA	26% for AF; 6% for LA flutter	77%	74%	4%
Pappone et al. 2006 (APAF)	I35	198	55 ± 10 (ablation) 57 ± 10 (AAD)	Paroxysmal	≥2 (mean 2 ± 1)	CPVA + CTI ablation	6% for AF; 3% for atrial tachycardia	42%	86%	22%
Jais et al. 2008 (A4 study)	I33	112	51 ± 11	Paroxysmal	≥1	PVI ± LA lines ± CTI ablation	Mean 1.8 ± 0.8, median 2 per patient	63%	89%	23%
Forleo et al. 2008 ^f	Online	70	63 ± 9 (ablation) 65 ± 6 (AAD)	Paroxysmal, persistent	≥1	PVI ± LA lines ± CTI ablation	Not stated	Not stated	80%	43%
Wilber et al. 2010 (Thermocool) ^g	96	167	55.5 (ablation) 56.1 (AAD)	Paroxysmal	≥1 (mean 1.3) ^h	PVI ± LA lines ± CFAEs ± CTI ablation ± RA lines	12.6% within 80 days after 1st procedure ⁱ	59% ^c	66%	16%
Packer et al. 2010 (STOP-AF) ^j	Online	245	56.7 (ablation) 56.4 (AAD)	Paroxysmal	≥1 ^b	Cryo-FAE ± CTI	19% within 90 days after 1st procedure	79%	69.9%	7.3%


Rhythm outcome after catheter ablation compared to cardioversion and AAD in patients with persistent or long-standing persistent atrial fibrillation

Freedom from recurrence of atrial fibrillation or atrial arrhythmias, comparing catheter ablation with antiarrhythmic drug therapy in patients with persistent or long-standing persistent atrial fibrillation



AAD = antiarrhythmic drug therapy; CI = confidence interval; N = number of patients; RR = risk ratio; W = study weighting.

Figure 17 Indications for catheter ablation of symptomatic AF





^aSignificantly enlarged LA volume, advanced age, long AF duration, renal dysfunction, and other cardiovascular risk factors. ^bIn rare individual circumstances, catheter ablation may be carefully considered as first-line therapy. ^cRecommended to reverse LV dysfunction when tachycardia-myopathy is highly probable. ^dTo improve survival and reduce hospitalization.



Cas clinique ce matin


- Patient de 65 ans, FA symptomatique
- HTA, DNID, SAS, obésité
- Longue histoire de FA parox devenue persistante depuis environ 1 an
- OG peu dilatée

OG 160 ml, substrat très hétérogène, veines modérément connectées



Isolation large des veines + Box post





Potentiel dissocié dans la box / activation en RS

© 2023 Congrès du CNCH, Tous droits réservés - Toute reproduction même partielle est interdite.

2023 © 29^{ème} Congrès du CNCH, Tous droits réservés - Toute reproduction même partielle est interdite.

Faut-il faire plus que les veines ?

- Repose sur l'isolation électrique des VPs +++
- Lésions additionnelles selon le type de FA (parox vs. persistante) et le profil du substrat atrial
 - « Tailored approach » plutôt que stratégie systématique
 - Taille de l'OG
 - Voltage du substrat
 - Veines connectées et actives ?
 - Primo ablation ou récidive ?
 - Attention aux flutter G secondaires
 - Less is more !
 - Balance bénéfice / risque et consentement éclairé

La FA: une prise en charge multidisciplinaire




Figure 10 Components of integrated AF management. AF = atrial fibrillation; HCP = healthcare professional; MDT = multidisciplinary team.

